From FDA Reviewer to Medtech CEO

Interview with Zenflow CEO Shreya Mehta

Listen to the Episode

0:000:00

Listen to the Episode

0:000:00

About the Guest

Shreya Mehta is the co-founder and CEO of Zenflow, a medical device company focused on treating benign prostatic hyperplasia (BPH). A biomedical engineer, she brings over 15 years of experience in medtech, including serving as a lead reviewer at the FDA, where she specialized in cardiovascular devices. Shreya co-founded Zenflow in 2014, out of the Stanford Biodesign Innovation Fellowship. The company was one of the first medical device startups backed by Y Combinator and also received early support from StartX and the UCSF Rosenman Institute at QB3.

Interview Summary

Shreya Mehta closed a Series C $24 million financing round for Zenflow just four days after giving birth to her daughter in 2024. "My daughter was born on Sunday night, and I literally had her in one hand and DocuSign in the other on Monday morning," Shreya recalls.

This high-stakes multitasking came during a pivotal moment in Zenflow's decade-long development of the Spring System, a minimally invasive treatment to relieve symptoms related to benign prostatic hyperplasia (BPH). The device uses a small spring-like coil to gently prop open the urethra, improving urinary flow while preserving the patient's anatomical structures.

"Our approach in particular is really unique in that we deliver not just with a gentle implant, but also a flexible system," Shreya explains. "It doesn't require any catheterization after the procedure. Then most importantly, the implant is removable, making the procedure totally reversible."

This combination of features enables the procedure to be performed in a urologist's office with minimal recovery time, and its reversibility addresses a significant concern for patients considering treatment.

Zenflow has positioned the device as a first-line therapy. "By virtue of it being a much more patient-friendly procedure and approach, we think that we can open up the market to many millions of more patients. Obviously, billions of dollars is a larger market opportunity," she says.

Zenflow has treated approximately 300 patients through pilot and pivotal studies and is preparing for PMA approval with commercialization expected in 2026. The company's journey offers valuable insights for other medical device entrepreneurs navigating the complex terrain from concept to commercialization.

Key Learnings From Shreyaโ€™s Experience

  • Design your product to address unmet clinical needs โ€” the technology should follow from there. Once Zenflow identified gaps in BPH treatment, the team focused on developing a solution that met patientsโ€™ desire for a flexible and reversible system, even in the face of technical challenges. This patient-centric approach informed engineering decisions and ultimately defined the Spring Systemโ€™s value proposition in the market.


  • Treat FDA relationships as strategic business partnerships. With experience on both sides of the regulatory process, Shreya emphasizes building rapport with reviewers, noting it can lead to more productive outcomes โ€” but just as important is the value of strong clinical evidence. Even if it means pursuing a more rigorous path like a PMA, solid data doesnโ€™t just support approval โ€” it drives adoption, reimbursement, and exit potential.


  • Leverage accelerator programs like Y Combinator and StartX to support the transition from academia to business โ€” not just for fundraising, but to build essential business fundamentals and community support. For Zenflow, these accelerators helped transform its concept from "just an idea" with prototypes into a structured company with clear business parameters.

Ground Your Device in Unmet Clinical Needs

For Shreya, a key lesson is to focus on genuine patient problems โ€” technology should follow. 

"One of the things I say is always start with the unmet clinical need," Shreya says. "Ground yourself in that. [Technological potential] is really tempting as an engineer, especially. We like toys. We like complex systems.โ€ But if your product isn't addressing a meaningful gap in care, the technical bells and whistles won't matter. โ€œIt's already difficult to survive in the startup world," Shreya adds.

This philosophy was tested early in Zenflow's development when the team faced pressure to abandon their flexible delivery system approach in favor of a more technically straightforward rigid design. 

"I was challenged very early on. I started off as CTO at the company, and it's like, Can we just do this through a rigid system?" she recalls. "At the end of the day, the patient friendliness of this approach is what's going to drive the market and adoption. We were persistent โ€” some might call it stubborn โ€” [about sticking] with a flexible approach."

Similarly, the team identified removability โ€” and therefore reversibility of the procedure โ€” as another critical unmet need. This feature addresses a significant psychological barrier for patients contemplating treatment for a sensitive condition.

"When men have BPH issues, it's the first time that something's happening below the belt that isn't pleasure," Shreya observes. "For men, it's a very private decision. It's something that's really meaningful to them."

By allowing patients to try the treatment with the assurance it can be reversed if needed, Zenflow's approach mirrors the familiarity of medication: "It's similar to drugs. If it's not working for you, if you're having a side effect that's not worth the benefit, you can stop taking the drug. Similarly, you can have the implant removed."

When facing technical challenges with the flexible delivery system, Shreya's team could have taken the easier path and limited the productโ€™s flexibility. Instead, they stayed grounded in the patient's perspective. "If that piece of your technology is likely to be the game changer, the difference maker in this space, then lean into it," she advises. "There are always shortcuts and easy ways out. But if you're grounded in what's most importantโ€ฆthe patient's decision, then I think youโ€™ve got to stick to your guns."

Zenflowโ€™s commitment to prioritizing patient needs paid off. It gave the team a clear benchmark: every technical decision had to support their ultimate goal of creating a solution patients would willingly choose over existing options.

Firsthand observation played a critical role in identifying real clinical needs and keeping the team aligned. It helped them stay focused, grounded in the belief that they were working from accurate, experience-based insights. Instead of relying solely on physician interviews or market reports, Shreya champions an immersive, in-person approach โ€” one that puts entrepreneurs directly in the clinical environment.

โ€œAny opportunity you have to be alongside key opinion leaders, physicians, or even nurses in the field or operating room โ€” take it,โ€ she advises. โ€œWith firsthand observation, you learn far more than whatโ€™s conveyed verbally.โ€

Treat FDA as a True Partner 

Having sat on both sides of the regulatory table โ€” as an FDA reviewer and now as a startup CEO navigating the PMA process โ€” Shreya offers valuable perspective on how to work effectively with regulators. Her central insight: treat regulatory relationships as critical business partnerships, not just bureaucratic obligations.

She highlights a common industry oversight โ€” medical device companies often invest significant effort in building ties with suppliers, vendors, and financial institutions, but neglect to cultivate similar rapport with regulators. This missed opportunity can have real consequences, potentially affecting both approval timelines and outcomes.

While maintaining professional boundaries, Shreya emphasizes the importance of building authentic connections with reviewers. โ€œYes, theyโ€™re regulators, and you have to be thoughtful about what you say โ€” but at the end of the day, itโ€™s still about relationships,โ€ she explains. โ€œYou need to invest in building a rapport with your reviewer.โ€

Companies that take this approach often see tangible benefits. โ€œI was often on a text basis with my best companies,โ€ Shreya recalls of her time at the FDA. โ€œThat doesnโ€™t mean it wasnโ€™t professional, but having that relationship and being able to get questions answered quickly โ€” thatโ€™s going to be to your companyโ€™s benefit.โ€

While it can be tempting to pursue the least burdensome regulatory path, Shreya is a believer in pursuing a PMA when it makes sense โ€“ oftentimes, these are the big and bold unmet needs. 

โ€œDonโ€™t necessarily shy away from a PMA path,โ€ she advises. โ€œEven if you have a Class II device, oftentimes you donโ€™t see the level of adoption you expect until you gather clinical data on that device.โ€

She points to industry data linking strong clinical evidence with better exit outcomes. โ€œBy virtue of pursuing a PMA โ€” you might have to run a randomized controlled trial โ€” but thatโ€™s building real value,โ€ she says. โ€œYou might feel a little burdened by the regulatory path, but I think itโ€™s okay to pursue that because youโ€™re strengthening the company.โ€

Shreyaโ€™s mindset and focus on the bigger picture helped the Zenflow team navigate the complexities of the PMA process. Rather than viewing regulatory hurdles as setbacks, they treated them as opportunities to improve their product and reinforce their market position. The clinical evidence collected through their pivotal trial has not only supported their submission but also bolstered credibility with physicians and strategic partners.

Shreya underscores that the benefits of clinical data extend well beyond approval. โ€œThat clinical evidence is everything โ€” even from a reimbursement standpoint,โ€ she notes.

Leverage Accelerator Programs for the Academia-to-Business Transition

For Zenflow, participation in prominent startup accelerators like Y Combinator and StartX played a crucial role in transitioning from academic concept to viable business. Shreya credits these programs with providing not just fundraising opportunities, but essential business frameworks and community support.

Shreya says the programs provided structure around business fundamentals that technical founders often lack: "It gave us a lot more parameters around the business side of things. Fundraising, obviously, is something that we had to work on, but also resources around IP."

Beyond formal programming, Shreya notes the value of connecting with entrepreneurs at similar stages of company development. "Having the community of those other startups surrounding us in the same place of evolution of their company was really helpful," she says. "Sometimes you just need a sounding board from people who are going through the same thing that you are."

The accelerator experience culminated in Y Combinatorโ€™s Demo Day, which helped the Zenflow team secure initial financing โ€” an important milestone in the company's journey from Stanford lab project to venture-backed startup.

Final Thoughts: The Path Forward

With PMA approval and commercialization targeted for 2026, Zenflow is preparing for the next phase of its development. The company plans to expand its commercial team later this year.

Shreyaโ€™s experience navigating both technical and business challenges offers several practical takeaways for medtech entrepreneurs. First, she emphasizes resilience when facing inevitable setbacks: "There'll be things that feel like you took two steps forward and one step back, but that's still progress. And sometimes we learn best from those setbacks."

Second, she advises entrepreneurs to actively seek out and incorporate critical feedback: "Don't surround yourself with yes-men. Surround yourself with people who are going to challenge you." This approach helped Zenflow refine its technology and business strategy over time.

Perhaps most importantly, Shreya underscores that patient impact remains the driving force behind the work. โ€œIt has been most gratifying to see patients truly affected by this technology,โ€ she says, recalling how physicians have shared stories of patients moved to tears by their symptom relief.

โ€œItโ€™s those moments that keep me and the team going every day,โ€ Shreya adds. โ€œThatโ€™s why we do what we do in medtech.โ€

Check Out the Podcast โ†’

Sponsors

  • FastWave Medical: Named MD+DI's Company of the Year, FastWave is one of the hottest medtech startups in the cardiovascular space. See how you can invest here.

  • Fundraising Cohort: Planning to raise capital for your startup? This live, 4-week workshop, led by Scott Nelson, is designed to help founders and CEOs tell a sharper story, get investor meetings that matter, and close real capital. Join the waitlist here.

Donโ€™t Forget

Interested in advertising with us?
Get in Touch โ†’

Want to learn from more startup CEOs?
Check Out the Archive โ†’

Forwarded this email?
Join for Free โ†’

Who's Scott Nelson again?
See His Bio โ†’

Transcript

0:00:00 [upbeat music] You have to make sure that you're building a relationship with your reviewer.

0:00:06 I was often with my best companies on a text basis, and it's just like, that doesn't mean it's not formal, but building that relationship and being able to, to bat questions quickly, that's going to be to your company's benefit.

0:00:19 And so take time, build that relationship, build the trust with your reviewer and that'll get you a long way.

0:00:27 Welcome to MedSider, where you can learn from the brightest founders and CEOs in medical devices and health technology.

0:00:34 Join tens of thousands of ambitious doers as we unpack the insights, tactics, and secrets behind the most successful life science startups in the world. Now, here's your host, Scott Nelson. Hey everyone, it's Scott.

0:00:48 In this episode of MedSider, I sat down with Shreya Metze, co-founder and CEO of Zะตะฝflo, a medical device company focused on treating BPH.

0:00:55 A biomedical engineer, she brings over 15 years of experience in med tech, including serving as a lead reviewer at FDA, where she specialized in cardiovascular devices.

0:01:03 Shreya co-founded Zะตะฝflo in 2014 out of the Stanford Biodesign Innovation Fellowship, and interesting enough, the company is one of the first medical device startups backed by Y Combinator.

0:01:13 Here are a few of the key things that we discussed in this conversation. First, design your product to address unmet clinical needs. The tech should follow from there.

0:01:21 Once Zะตะฝflo identified gaps in BPH treatment, the team focused on developing a solution that met patients' desire for flexible and a reversible system, even in the face of technical challenges.

0:01:30 This patient-centric approach informed engineering decisions and ultimately defined the spring system's value proposition in the market. Second, treat FDA relationships as strategic business partnerships.

0:01:40 With experience on both sides of the regulatory process, Shreya emphasizes building rapport with reviewers, noting it can lead to more productive outcomes. But just as important is the value of strong clinical evidence.

0:01:51 Even if it means pursuing a more rigorous path like a PMA, solid data doesn't just support approval, it drives adoption, reimbursement, and exit potential.

0:01:59 Third, leverage accelerator programs like Y Combinator and StartX to support the transition of academia to business, not just for fundraising, but to build essential business fundamentals and community support.

0:02:09 For Zะตะฝflo, these accelerators help transform its concept from just an idea with prototypes into a structured company with clear business parameters.

0:02:17 All right, before we dive into this episode, I'm pumped to share that volume seven of MedSider Mentors is now live.

0:02:23 This latest edition highlights key takeaways from recent MedSider interviews with incredible entrepreneurs like Bill Hunter, CEO of Canary Medical, Brian Lord, CEO of Pristine Surgical, Don Crawford, co-founder of Saphion and current CEO of Corvista Health, and other proven med tech founders and CEOs.

0:02:38 Look, we get it. Keeping up with every MedSider interview isn't easy. That's why we created MedSider Mentors.

0:02:42 These e-book volumes distill the best practices and insider secrets from top founders and CEOs, all in a downloadable, easy-to-digest format. To check the latest volume out, head over to medsiderradio.com/mentors.

0:02:55 Premium members get free access to all past and future volumes, plus a treasure trove of other resources. If you're not a premium member yet, you should definitely consider signing up.

0:03:04 We recently revamped MedSider with swanky new features, especially for our premium members. In addition to every volume of MedSider Mentors, you'll get full access to our entire interview library dating back to 2010.

0:03:15 You'll also get MedSider playbooks, curated guides packed with actionable insights on topics like fundraising, regulatory challenges, reimbursement strategies, and more.

0:03:23 And if you're fundraising, don't miss our exclusive investor database featuring over 750 life science VCs, family offices, and angels. We've even created three custom packages to help you with your next fundraise.

0:03:34 Learn more about MedSider mentors and our premium memberships by visiting medsiderradio.com/mentors. All right, without further ado, let's dive into the interview.

0:03:43 [upbeat music] All right, Shreya, welcome to MedSider Radio. Appreciate you coming on. Thank you for having me, Scott. I'm looking forward to it. I know.

0:03:52 This has been, like, a long time in the making it feels like, so it's good to- It has. Yeah... to finally have you, have you on the program.

0:03:56 Really looking forward to, to learning about, like, the past 10 years at Zะตะฝflo, right? As a co-founder, now, now CEO of the company, and I think it'll be fun to, to chat about kind of the, the journey, right? Yeah.

0:04:05 Going from engineer to entrepreneur. But, uh, with that, with that said, I, I recorded a, a very short bio at the outset of this, uh, this interview, but let's start there.

0:04:13 You know, give us maybe a, a couple minute overview, right? Of your, of your background leading up to co-founding the, the company, now leading, leading it as a, as CEO. So I'm a biomedical engineer by training.

0:04:22 I'm an engineering nerd. You know, I worked in R&D in my early career in manufacturing R&D at St. Jude Medical, and then from there I went into graduate school and I transitioned actually more into a regulatory career.

0:04:39 So I worked at FDA for a number of, of years, worked on Class 2, Class 3 devices. I did probably hundreds of 510[k]s, IDEs, PMAs, ran a panel meeting. You know, all of those were in the cardiovascular space.

0:04:55 But in, nonetheless, you know, I think having the background of having been on the other side of the table, um, at FDA has been really educational and happy to have had that experience.

0:05:06 That being said, you know, I kinda wanted to-- I didn't wanna pigeonhole myself into being just on the regulatory career path.

0:05:14 I found out about a program at Stanford called the Biodesign Innovation Fellowship and, you know, honestly wanted to move out to the West Coast, so California.

0:05:23 So applied to that fellowship program, and what I was really seeking to do was to gain a little bit more of a holistic perspective on how medical technology becomes successful, right?

0:05:34 So it's not just the regulatory aspect of things, but also how does reimbursement work? How do you, you know, raise financing?

0:05:42 Um, how do you think about IP and strategy, and how do you actually build a successful product and business?

0:05:47 And so applied to that fellowship program and got in in, um, 2013, and then, uh, spun Zะตะฝflo, the company that we'll talk about today, uh, out from the Stanford Biodesign Innovation Fellowship.

0:06:00 And as you touched on, it's been about 10 years now since starting that company, and it's been, it's been quite the ride. Yeah, I can imagine.

0:06:07 And there's, you know, there's been, um, I guess we've done probably close to 300 now interviews with, uh, with founders and, and, and C- med tech CEOs.

0:06:14 I think you might be the first one that's sorta sat on the other side of that particular table, right? The reg table, right? Mm-hmm. Sometimes we'll-- I'll have investors, right?

0:06:20 That are now operating a, a company and, um, can sit on both sides. But, uh, it's a definitely unique experience. I bet, uh, I bet it's, it's paid off, right? In, uh, in, in spades.

0:06:28 Um, especially with the novel, novel technology, right? That you're, you know, developing at, at Zะตะฝflo, so, um- Absolutely. Yeah... yeah. Uh, that's cool.

0:06:36 Well, on, on that note, tell us about the, the, the spring system, right? Uh, give us a, a sense for kind of like what, what the disease or major problem, like, you're trying to solve.

0:06:43 Maybe what standard of care versus, you know, how, how this, how this device is different. Yeah. So standard of care is the right place to start, right? Yeah. So by design, I've drunk the Kool-Aid from by design.

0:06:53 They tell you you start with the unmet need, and when we were there at Stanford, we met so many urologists, we met so many patients who were suffering from enlarged prostate or benign prostatic hyperplasia.

0:07:05 So what happens as the prostate grows, it creates obstruction. Patients have a terrible quality of life issue based on that growth.

0:07:12 And so what we developed was a gentle spring-like device that props open the prostatic urethra and allows men to urinate more freely.

0:07:23 So our approach, in particular, is really unique in that we deliver not just with a gentle implant, but also a flexible system.

0:07:32 Doesn't require any catheterization after the procedure, and then most importantly, the implant is totally removable, making the procedure totally reversible. Wow.

0:07:43 And what this means is that, you know, we get to open up the BPH market. So there are technologies out there for BPH, and what the-- our particular approach means is that we open the market to first-line therapy. Mm.

0:07:58 So by virtue of it being a much more patient-friendly procedure and approach, we think that we can open up the market to many millions of more patients, obviously billions of larger market opportunities. So our...

0:08:11 You know, it really started with the unmet need, and by virtue of the technology is where, is where the, the market really opens up to a new category. Got it. Uh, and I'm on the website now, which is zenflow.com.

0:08:22 We'll link to it in the full write-up on MedSider, but for those listening, it's Z-E-N Flow, just as it sounds. Cool name, by the way. Uh, I lo- I love the name. Thank you. Um, I've always- Thanks...

0:08:30 I've al- always, always liked it when I first heard about Zenflow. But, um, just to kind of drill, drill down in the technology itself, let's say I'm a patient.

0:08:37 I may be eligible for this as a, as a frontline therapy, I presume because it's, it's so minimally invasive. This is done in, in the, in the, in the clinic, right, in the urologist clinic?

0:08:44 I don't have to go to probably- That's right... a hospital for this. Okay. Got it. Yeah. It- it's implanted. How long is the implant left, left behind before it's, it's removed?

0:08:50 So it's a, it's a permanent implant, and so it's- It's reversible. You said it's reversible. Mm-hmm. Okay, got it. So- It's intended to be permanent, but it can be removed. And yeah- Ah...

0:08:57 it's, it's similar to, you know, we kind of make the analogy similar to drugs. It's like you, you start taking drugs.

0:09:03 If it's not working for you, if you're having side effect that's not worth the benefit, you can stop taking the drug. Similarly, you can have the implant removed. Oh, that's interesting. Okay. Okay, got it.

0:09:13 And then the likelihood of someone wanting it to be removed, is it like, is it-- are we talking like a, it's a, it's a pretty low percentile, I, I would imagine? It is. Yeah. Yeah. No, we don't...

0:09:22 You know, our, our removal data is on par with other BP... or I should say our re-intervention data is on par with other BPH therapies out there.

0:09:31 But, you know, at the end of the day, I think what we're doing is we're really driving the patient decision, right? Mm-hmm.

0:09:36 And again, by virtue of that and ability to fully reverse, we think patients will elect to undergo a procedure like this perhaps earlier than they might have otherwise. Definitely.

0:09:47 And that's, that's really where we see the huge, yeah, huge opportunity. Yeah.

0:09:52 I can, I can only imagine, right, to overcome some of that maybe inherent skepticism of having, you know, an implant, right, in a rather a kind of sensitive area and, and having that optionality, right, to have it, you know, hey, if this doesn't go as planned or I don't like the results, it can be removed, and we start, you know, from scratch almost.

0:10:06 Yeah. And that's one thing I'd like to highlight too, is when men have BPH issues, it's kind of the first time that something's happening below the belt that isn't, you know- [laughs]... relief or pleasure. Yeah. Right?

0:10:16 Um, and for, for women, it's a very different experience. But for men, it's such a, it's, um, it's a very private decision, right? Yeah.

0:10:24 And it's something that's really meaningful to them, and so that was another reason why just we wanted to make sure that it was a truly patient-friendly approach. Yeah. Yeah, I can see why.

0:10:33 One of my, one of my friends, um, had... I'm, I'm not even sure if he had BPH or maybe it was like early onset of BPH. I can't remember, but he's not- Yeah... he's not that old. Um, but he's in, in, in Dubai. Yeah.

0:10:42 Had a procedure done, not, not with Zenflow at all. It was like some other device, and it didn't go very well, put it that way. And so I can, I can imagine- Yeah...

0:10:48 like I'm not, I'm not overly familiar with like the urology space in, in great detail, but I can imagine, right, just if he, if he's presented with an option, right, where it's like, "Hey, this doesn't, this, you know, this can always be removed, right, down, down the road"- Right...

0:10:59 that's, that's, uh, that, that's especially important. So, um- So why not? Yeah, exactly. Exactly. Why not give it a shot? So well, that's cool. Uh, with that said, we're recording this in early Q2 of '25.

0:11:07 For those listening kind of down, down the road or maybe re-listening to this down the road, where's the company at in terms of kind of its, its life cycle? Yeah.

0:11:14 So we've treated about 300 patients now, um, in the context of several pilot studies and then our pivotal study most recently. And, uh, we're preparing at this point for PMA approval and commercialization.

0:11:27 So we're kind of right at the precipice- Mm... of that sort of, you know, clinical validation and transferring the design to commercialization, which we're really excited about.

0:11:36 So we expect the product to be on the market in '26, which is gonna be here before we know it. [laughs] Yeah. No doubt. Yeah. I mean, we're like almost, almost midyear, right? Yeah.

0:11:45 You know, not too far away, mid, mid '25. So a lot... What a, what a, what a cool time, though. I mean, not, not too many med tech startups kind of make it, make it this far, right?

0:11:52 So to be, to be on the precipice of, of commercialization, that's, that's pretty cool, especially with a PMA device. So- Yeah. It's exciting, right... yeah, no doubt.

0:11:58 With that said, let's, let's spend the next 20 or 30 minutes kind of going back in time and, and I'd love to learn a little bit more about the journey getting here, right, over the past, you know, decade or so.

0:12:05 Uh, but again, for everyone listening, it's zenflow.com. Z-E-N Flow. Zenflow.com, just as it sounds, and highly encourage everyone to check out the device, uh, and the company in more detail.

0:12:14 But first question on, on the docket is, uh, especially considering your co-founder engineering background, I'm sure the current system, right, or the current device that you expect to commercialize didn't, didn't look the, the same way, right, when you were first developing it, you know, 10 years ago coming out of the, the, the biodesign program.

0:12:29 When you think about as a, as a startup, right, having to do a lot with typically a, a small amount of resources and trying to iterate quickly, you know, for, for other, you know, newer med tech entrepreneurs, right, that don't, that don't have, you know, that ha- haven't had the, the experience or, you know, been at, been at the plate to take some swings, how do you encour- you know, typically encourage them to kind of work through those early stages, right, while trying to conserve as much cash, but also be able to kind of show, show progress at the, at the same time?

0:12:55 One of the things I like to say is always, always, always start with the unmet clinical need, right? Ground yourself in that. It's actually really tempting as an engineer especially. We like toys.

0:13:06 [laughs] We like, you know, complex systems.

0:13:08 I think at the end of the day, if your technology is not addressing the big picture unmet need- You know, you already have a-- it's already difficult in the startup world to survive, and I think if you're going technology first, that makes it even harder.

0:13:23 Hmm. Um, so always start with the unmet clinical need. One example of this is we had...

0:13:28 our approach is through a flexible system, which is a huge game changer in this space, and it was technologically difficult, you know, from an engineering standpoint to advance a flexible system through all these trials and whatnot.

0:13:42 And so I was challenged very early on. I started off as CTO at the company, and it's like, "Can we just do this through a rigid? Can we just..."

0:13:49 And at the end of the day, the patient, you know, friendliness of this approach is what's going to drive the market- Hmm... and adoption.

0:13:57 And so we were persistent, some might call it stubborn, uh, with a flexible approach and, and we stayed grounded in that need,, and how we, our vision for developing this market, and I think that was, that was to our advantage certainly.

0:14:10 Were there, were there... I, I kinda think there's times, like, along the road, right, where you're getting pressure to, like, you know, to go, to go to that rigid system, right?

0:14:16 Or to just, you know, "Hey, pivot or flex on that," that kind of mandate, right, that technological mandate.

0:14:21 For others that are-- maybe are going through that, like, and trying to make that decision, do we stick to our guns or, or pivot, any, any words of wisdom?

0:14:27 I think if that piece of your technology is what you think is going to... is that the game changer? Is that the difference-maker- Hmm... in this space?

0:14:37 Then lean into it and, you know, there's always shortcuts and easy, easy ways out.

0:14:43 But I think if you're grounded in that which is most important, which is at the end of the day the patient's decision, then I think you gotta, you gotta stick to your guns. Yeah. Yeah, that's good. Yeah. Good stuff.

0:14:54 The benefit that we, that we touched on earlier, the, the optionality, right, of having, you know, kind of being able to kind of reverse this, right, or remove the implant.

0:15:01 Was that, was that another kind of big unmet need that you identified quite early on, too? Absolutely, yeah. Yeah.

0:15:06 Removability, which means reversibility of the procedure, was critical, so the implant design in particular was-- it was designed to allow for- Hmm... removability.

0:15:17 Um, and it was always intended to be permanent, but ease of removability is something that is, is important for physicians and patients. Got it. Got it.

0:15:25 Thinking back to either your time at Biodesign or even early at Zennflo, and you're trying to identify, like, what are the big, the big unmet needs here, are there some things that kind of, like, help you kind of narrow in on what, what you should, what you should develop?

0:15:38 Or maybe sort of tips to really kind of, like, I guess focus a little bit. 'Cause y- you know, I'm always reminded, you know, we talk about kind of the unmet need.

0:15:45 I'm always reminded me of, uh, that, that or reminded of that, uh, that Henry Ford quote, right? Like, "If I would've listened to people, you know, I would've just, you know, built a faster horse" or whatever.

0:15:52 Can't remember exact phrase he used. Right. But, but, you know, you can see how people would, would, would gravitate towards that, right?

0:15:56 If I listen too much to people and they don't really know what's possible, you know, I could, I could get stuck kind of building the wrong, the wrong thing.

0:16:02 So any thoughts kind of on, on, on navigating that, uh, during kind of early stage development? Yeah. I think one thing that we did is we-- you, you obviously should listen to your customers, right? Mm-hmm. Mm-hmm.

0:16:12 But you also have to just-- there's a benefit to firsthand observation. Hmm. And Biodesign drives that home.

0:16:19 I think e- early entrepreneurs, you should, you know, any opportunity that you have to be alongside some of the KOLs in the space or physicians who are working in the field or even nurses who are working in the field or in the operating room, go and observe firsthand.

0:16:33 Hmm. 'Cause with that observation, I think you learn, you know, more than you might just what's conveyed verbally. Yeah. That never ceases to amaze me, right?

0:16:41 Like, how much-- how many little things you pick on by just being so close to the, to the end user, right? And it could be, could be a physician- Yeah...

0:16:47 could be patient, could be, you know, a different type of stakeholder kind of in that workflow. But, like, just- Yeah...

0:16:52 the, the more intimately involved you are, like, it, it just-- it alway- it-- you know, there's always, there's always learnings, right, that are, that are picked up. Definitely. So yeah, it's good stuff. Yeah.

0:16:59 Um, let- let's talk a little bit about the, the, the, the clinical roadmap, right?

0:17:02 You started at-- l- based on our research, it looks like you started the pivotal trial in 2021, and are now kind of, you know, close to submitting for, for PMA approval.

0:17:10 You know, kind of a- again, uh, almo- almost to the commercialization stage.

0:17:15 When you think back to your times at, at, at FDA, right, sitting on that side of the table, now, you know, developing a, a novel system that gets to the stage of, you know, of, of a, of a full, you know, PMA pivotal trial.

0:17:25 As you've kind of thought, you know, been, you know, knee-deep in that, that, that reg clin kind of pathway, you know, what are, what are a couple key things that you've, that you've kind of learned now being on the, on the industry side over the past decade?

0:17:36 Yeah. One thing I'll say is that don't necessarily shy away from a PMA path, [laughs] right? Hmm.

0:17:43 So it's-- sometimes conventional wisdom sort of dictates the easier the regulatory path, the better off you are, and I think, I, I think you-- you know, there is a balance there.

0:17:53 I think one of the things that we've seen... You might know John Norris. Um, he was at SVB. Now he's at HSBC.

0:17:59 He always presents on, you know, the annual healthcare report, and one thing that I think I've seen very consistently from him in the last, like, 10 years is when it comes to exits, we actually see, even if you have a Class 2 device, oftentimes you don't see the level of adoption that you really expect until you gather clinical data on that device.

0:18:20 And so in any case, you're, you know, you're look at-- your medical device is hard [laughs] and it takes many years to develop the level of rigor that's required for, let's say, a larger company to consider acquisition.

0:18:33 And so don't shy away from the PMA because by virtue of that, you're gonna have to do-- let's say you have to do an RCT. That's building value.

0:18:40 It's building really important value, and you might feel, you know, a little burdened by the regulatory path.

0:18:46 But I think it's okay to pursue that because you're, you're building value in the company, and at the end of the day, hopefully that means, you know, greater acquisition potential, too. Yeah.

0:18:55 Yeah, there's, there's an inherent moat, right, in, in overcoming, you know, much, much taller hurdles, right? I.e., more rigorous regulatory pathways. That's really good feedback.

0:19:03 When you, when you, you even take a step back and think about, you know, what, what companies are truly venture backable, in a lot of cases they're, you know, it's not cla- a Class 2.

0:19:11 In some, you know, in some, in some regards it could be a Class 2 device, but typically, even if it's a Class 2 device, it's something that's gonna require clinical, clinical data or a little bit more rigorous, rigorous, uh, kind of a, a reg, reg pathway.

0:19:22 So- Yeah, that, I mean, that clinical evidence is, is everything, even, even from a reimbursement standpoint too. Yeah.

0:19:28 I, I'd be remiss if I didn't, if I didn't mention this at, uh, or ask this too, um, kind of on the, on the same topic. But when you think back to your time, right, at FDA, and now, you know, now going...

0:19:37 um, I'm sure engaging with FDA quite a bit, right, over the past, uh, over the past decade. Any other tips that come to mind, right, on how, you know, industry could do a better job of engaging with, with, with FDA?

0:19:48 You know, one thing that always surprised me on the other side of the regulator table is that businesses often consider, companies like ours consider business relationships with, let's say, supply chain vendors, right?

0:20:00 And it's, um... or even the bank that you work with.

0:20:02 And, and I always, I think that on the other side of the table, it felt like oftentimes companies weren't considering that with the same level of business relationship- Mm...

0:20:13 as they might with other parties that they're working with.

0:20:16 And yes, they're a regulator, and yes, you have to be formal and careful about what you say, et cetera, but I think at the end of the day, it comes down to relationships too, and you have to make sure that you're building a relationship with your reviewer.

0:20:30 You know, I was often with my best companies on a text basis, right? Mm-hmm.

0:20:35 And it's just like it, it's not, it, that doesn't mean it's not formal, but building that relationship and being, you know, being able to, to bat questions quickly, that's going to be to your company's benefit.

0:20:45 And so take time, build that relationship, build the trust with your reviewer, and that, that'll get you a long way. Yeah. That's a, that's a good way to frame it, right?

0:20:53 Like, if you're, maybe if you're, if you're not that close to your reviewers where you could maybe fire off a, a, a text, maybe you need to take a step back and kind of rethink how your [laughs]...

0:21:03 And so, uh, you just set a new bar, uh, Shriya, for how- [laughs]... how we should be, how should we be engaging with, uh- Text bases. Yeah... with folks at FDA. Yeah. Text base.

0:21:09 Invite to Slack or Teams, I guess your, your choice. Yeah. Uh, yeah, but, but joking aside, um, I, her name is escaping me, but she brought up something similar.

0:21:16 It's been a couple years since I had her on the program, but she's developing a concussion device, and that was one of her, her takeaways is that she viewed when she went to...

0:21:23 I mean, this is back when FDA was doing more in-person meetings, or that was maybe, like, kind of the standard, um- Yeah...

0:21:28 that, you know, it was always surprising to her, like, other people were just like, you have this pretty important, right, Q7 meeting or something like that, or, or, what- whatever meeting it is, right?

0:21:37 Let's take a Q7 example. And it was very transactional, right? There was no sense of like, "Hey, my name is Scott. I have X number of kids. I live in so and so."

0:21:46 [laughs] Like, there was no, like, getting to know you kind of, right? Or very little of that. No.

0:21:50 And, and it was like, you know, I actually, she, she l- took a little bit of a different path, right, to get to know the reviewers a little bit more, and she said that was one of the things, um...

0:21:57 Oculogica, that was the name of the company. What's her name? I can't remember. I'd have to go back and look it up. But, uh, but I thought it was really good.

0:22:01 It's really good feedback, you know, to know that, like, look, it's, it's, yes, it's transactional to a certain extent, but at the end of the day, it's, you know, you're, you're transacting with people, right?

0:22:09 It's people- Right... on the other side of the, on, on, on the other side of the table, right? You know, trying to- Yeah... in mo- in most cases, trying to march to- towards a similar goal. [upbeat music] Hey, everyone.

0:22:20 Let's take a quick break to talk about Fast Wave Medical, the company I co-founded and lead as CEO.

0:22:24 We're developing next generation intravascular lithotripsy systems, or IVL for short, to tackle complex calcific disease. The IVL market is valued at over $10 billion, but there's currently only one major player.

0:22:36 In early 2023, we opened up an investment opportunity to our community, and within a month we secured close to $10 million.

0:22:43 Then in early '24, we closed an oversubscribed $19 million round in just a few weeks, bringing the total investment into Fast Wave to over $40 million. Corporate interest in the IVL space is growing too.

0:22:54 The $900 million acquisition of Bolt Medical by Boston Scientific, and then J&J's $13 billion acquisition of Shockwave Medical signals a lot of attention towards emerging IVL startups like Fast Wave, and we're making some serious progress.

0:23:07 Fast Wave recently received its seventh patent for our differentiated laser IVL platform for coronary applications.

0:23:13 On the clinical side, last year we completed the first in-human study of our advanced electric IVL system with some pretty compelling results.

0:23:20 Next up in 2025, we have IDE trials planned for both our peripheral and coronary IVL platforms.

0:23:26 So if you're interested in investing in the fast-growing IVL market, sign up for our investor wait list at fastwavemedical.com/invest. Again, that's fastwavemedical.com/invest. Now let's get back to the conversation.

0:23:40 [upbeat music] Let's transition and talk about, about fundraising. In November, I believe, of last year, so late last year, announced the closing of a Series C, right? Yep.

0:23:50 Funding is never, never difficult, especially when the stock market is not doing so, so, so hot. [laughs] When tariffs abound and the stock market is, uh, is not doing so well.

0:23:59 Fundraising is always, always, you know, super challenging. I think even in, even in the best macro environments, it's, it's always challenging, um, especially in med tech. Med tech's a bit of a, bit of a unique class.

0:24:08 Um, so when you think about your, your journey, right? I mean, there, again, there's not a lot of companies that get to a, a PMA pivotal, let alone, you know, raise a Series C.

0:24:15 So are there a couple key things that, you know, have really been helpful, kind of, you know, helpful learnings for you, you know, fundraising for, for ZynFlow, um, over the, the past handful of years? Yeah.

0:24:24 I'll, I'll say yes, you're right. It's difficult. [laughs] It's always difficult and, and, you know, our Series C was no, was no exception.

0:24:32 But may- maybe this is a little bit tangential, but interesting story nonetheless. So I closed on Series C four days after my second daughter was born. Mm. Um, [laughs] and- Wow... and it's already hard, right?

0:24:46 Doing it while pregnant adds a, adds a layer of, of complexity and difficulty. And it was actually interesting because I was, you know, set to be induced on a Saturday.

0:24:58 Cook Medical joined the investor syndicate, so we had, you know, a strategic at the table. There were obviously lots of discussions happening behind the scenes there with their BD team and so forth.

0:25:10 And perhaps most surprising, they were, we were, we were all working toward closing as quickly as possible, of course, but I was like, "Okay, guys, I've got a real deadline." [laughs] "It's Saturday.

0:25:21 I mean, it is Saturday." So let's get this done. Yeah. And, you know, everybody was very... You know, we obviously had to dot all the I's, cross all the T's. I had a call with the BD guy on a Thursday.

0:25:32 There was one last term that needed to get an LOI on an emergency board meeting on Friday. We approved it. Saturday morning, I was on the call with our attorneys- [laughs]...

0:25:43 built out in the documentation Saturday night. Got induced. My daughter was born on Sunday night. Wow. And I was literally had her in one hand and DocuSign on the other on Monday morning. Wow. So I think don't...

0:25:56 It- it's sort of similar to what we said about regulatory.

0:25:59 Don't underestimate the value of those relationships and, you know, investors' willingness to- to work, [laughs] work with you on, on the details and get down to the nitty-gritty together. What a, what an amazing story.

0:26:11 It al- it always remind... I mean, maybe that's, uh, that's in its own kind of tier, right, with, uh, you know, being- being pregnant that- that close to, that close to delivery.

0:26:18 But, uh, I never, like, I never stop, you know, being amazed by, you know, founders, CEOs that, like, the challenges, right, that- that- Yeah... you go through in a, in a startup, you know.

0:26:27 And having a baby, uh, while closing a round of financing is- is right, is right up there, right, with, uh, with- with- with some of the- the more, the- the- the- the broader challenges.

0:26:35 But, uh, but yeah, I mean- Never a dull moment. Yeah. No, exactly. [laughs] Yeah. I mean, we're laughing about it. I'm sure it was probably quite, quite stressful at the time.

0:26:41 But, uh, yeah, if you're listening to this, that's sort of like the- the world of startups, right? It's like there's always- It is... fires to be, to be putting out.

0:26:47 It's, uh, rare that you see kind of, you know, you have a glimpse of smooth sailing, right, uh, maybe for- Exactly... short periods of time. But, uh, usually it's a pretty, pretty uphill climb.

0:26:55 But did you get a sense though, like, um, you know, I- I'm sure obviously everyone knew that you were that close to- to delivering. Did it, did it almost, um...

0:27:02 I gotta think, though, like, if I'm sitting, if I'm an investor and I'm watching you execute a financing that close to, you know, to- to delivering, it's like there's a certain amount of, like, you know, admiration of, like, this person's gonna, this person's [laughs] gonna, like, take the company to the finish line too if they're, you know, if they're DocuSigning while holding a newborn, right?

0:27:19 Um- [laughs] Did you get, did you get a sense for that, like a, like a bit of a almost a newfound respect, you know? Uh, yeah. I- I think that's true. Yeah. Yeah. I think so.

0:27:27 We have one other woman on- on the board, but most of them are men and, but they've watched- Yeah... you know, their own family members, wives, whatever, go through, go through that.

0:27:35 And I think, yeah, I think it speaks to our ability to execute even when things are- are tough and challenging- Yeah... and when you gotta balance things, and that's just, like you said, that's just startup life.

0:27:45 So- Yeah... you know, got it done. Yeah. [laughs] And that's what happens at the end of the day. Yeah. That- that- that's awesome. How- how's your little one sleeping, you know? I- I had- Oh, well. Yeah? Good?

0:27:54 Sleeping good? [laughs] I just got, I just got a text from my neighbor saying, "We bought earplugs," so. [laughs] That's funny. Oh, that's good. That's good. I think I need to take them a bottle of wine.

0:28:04 [laughs] Exactly. Exactly. Congrats on the, on the fundraise, and even bigger congrats on the, on the new, new, new little one. Um- Thank you. Yeah. But, uh, that's a fun, fun story.

0:28:14 Let's chat a little bit, I mean, it's kind of a bit of a similar topic, right? But- but you, but ZynFlow, you know, has had the...

0:28:18 Had the opportunity to go through some- some pretty prominent kind of accelerators, you know, for, I don't know, accelerators, incubators. You had Y Combinator, StartX, et cetera.

0:28:26 Those experiences, I mean, do you think largely they were, they were, they were beneficial?

0:28:30 And, you know, I guess what were, you know, are there, like, one or two kinda key takeaways, you know, kind of going through some of those, uh, th- th- some of those more prominent, uh- Yeah... accelerators?

0:28:39 Probably the biggest, the biggest takeaway, it really, you know, when we started at Biodesign, it felt like just a, it just felt like an idea, right? And we had prototypes. We knew the unmet need we were going after.

0:28:50 But really being, being involved with, especially, I would say, StartX and YC, really felt like we were going from an academic idea to a company. Hmm. Right?

0:29:01 It gave us, it gave us a lot more parameters around the- the business side of things. You know, fundraising obviously is something that we had to work on, but also resources around IP. You know, we did demo day at YC.

0:29:15 Obviously, we- we were raising financing there.

0:29:18 And so it just, you know, I think that transition was really important for us, um, and having the community of those other startups around us, kind of in the same, in the same place of evolution of their company was really helpful.

0:29:31 So we would... You know, the community around it and then just the building blocks of how to, how to start this company off the ground. I think those- Hmm... were really essential for us.

0:29:40 This question comes up, I- I don't, I don't want to say a lot, but, like, a- a fair amount of, like, a, you know, a startup that's, you know, maybe has a little bit of traction or, you know, is in- impatient and they're, you know, they're- they're- they're faced with that question, do I, do I really need to go to an accelerator, right?

0:29:52 What's the, what's the benefit of it, you know, at that certain stage? But it, it sounds like obviously, you know, uh, ZynFlow was- was the, you know, participated, you know, fairly early on.

0:29:59 But the- the network, right- Yeah... the community, um, kind of e- e- engagement sounds like it was- was worth the, worth the payoff. Yeah. And sometimes you just need, like, a sounding board from- Yeah...

0:30:09 [laughs] people who are going through the same thing that you are. Yeah, no doubt. No doubt. Well, cool. Let's talk a little bit about, about commercialization, right?

0:30:15 Considering you're- you're, you know, fairly, fairly close. Because this, this device does have more so maybe than most devices, right? Um, has, has a bit more of a, a patient connection, if you will, right?

0:30:26 Um, you're obviously con- you know, trying to convince, um, a urologist to, uh, to incorporate this as a, as maybe a frontline therapy, but also, you know, I'm not sure how much you're thinking about, like, D2C type of, type of marketing.

0:30:37 But give us a, give us a sense for how that, how that layers into kinda your, your overarching kind of approach to commercialization, knowing that you're, you're fairly close at this point. Yeah, absolutely.

0:30:45 I mean, I think patient awareness and physician awareness, both of them are our customers, right? Mm-hmm. To your point, one thing that we lean heavily on is our, is our clinical data.

0:30:53 So we have, you know, as I mentioned, we've treated about 300 patients so far in the context of our pilot and pivotal studies, and that data speaks for itself, right? Mm-hmm.

0:31:03 And now we are, as we're marching toward commercialization, we're considering how to frame that, you know, in a way that speaks to both of those audiences. So there is a big conference coming up for us.

0:31:15 The AUA, American Urological Association Conference, is coming up in three weeks. We're presenting on 36-month data. Mm-hmm. So that's our longer term outcomes from our pilot studies.

0:31:26 That's a point that we really wanna drive home, is that we have, you know, durability in both effectiveness and safety that we've seen over time, and that's a...

0:31:35 These are important features for our- our physicians and our- our patients alike.

0:31:39 We wanna, once we enter the market, I think having that rigorous data behind us speaks volumes, and so we're- we're really going to be leaning on that for a lot of our marketing and messaging next year. Got it.

0:31:51 When, when do you expect to begin to build out the, build out the commercial team for anyone, anyone listening that's maybe wants to join the- the ZynFlow train? Yeah. This year- Yeah...

0:31:59 or next year, we're, we've got lots of plans to build the team, so keep, keep an eye out with the recs on our website. Got it. That's cool.

0:32:06 Before we get to the rapid-fire portion of this, th- this interview, anything else, right? I mean, you c- co-founded the company, been at it for about a decade, you know, uh, for, if we're gonna r- round, uh, round down.

0:32:15 But, um, you know, anything else that- that we missed on or that you think is, would be especially kind of, uh, you know, impactful to- to kinda share with- with other aspiring, you know, founders or- or CEOs, uh, in med tech?

0:32:27 You know, it's, so it's been, like you said, a decade, right? Mm-hmm. That we've been going at this.

0:32:31 Um, we now have developed a solution that urologists and patients are, they- they clearly are actively seeking that we're excited to get on the market. The market's continuing to grow.

0:32:42 Like, the opportunity here is, is incredible. The thing I'll say that I think has been most gratifying is really seeing, seeing patients Truly affected by this technology. Mm. And, and it...

0:32:54 You know, we've had stories of physicians, you know, "The patient came crying to me in, in tears of joy because of their symptom relief."

0:33:02 And at the end of the day, you know, they benefit from this technology, and that's what keeps me and the team going every day is the effect that we can have on our patients, and- Mm...

0:33:12 treating their symptoms and improving their lives, right? That's why, that's why we do what we do in med tech, so. Yeah, no doubt. Um, yeah, that's, that's the... it's always the motive behind everything.

0:33:22 [clears throat] On, on that note, that's one of the...

0:33:23 the company that I started before, FastWave, we, uh, designed and developed a class II photobiomodulation device but commercialized it en- entirely online direct to consumer, 'cause it was just an OT- OTC device.

0:33:31 Oh, wow.

0:33:32 Um, and that was always the thing that, like, looking back on, 'cause I've, I'm previously spent most of my career in traditional, in traditional devices, right, where you're primarily selling to physicians and, you know, hospitals.

0:33:41 But it was, it was such a unique experience because the, the, the feedback loop was so tight. Mm.

0:33:46 Because, you know, someone that was suffering from eczema or some skin issue or some autoimmune dis- i- issue, right, you, you heard it.

0:33:51 Like, you get the feedback so immediately, and that was always, always so rewarding. I mean, we, we did sell, I guess, 20% maybe of the business was B2B or to, to clinicians. But yeah- Okay...

0:34:00 that feedback loop was, uh, was always so cool, right? I mean, 'cause you just- So cool. Yeah, yeah. It never, um... It'd be hard to build...

0:34:07 It hard, it'd be hard to do another startup outside of, like, healthcare or med tech specifically, 'cause, you know, that is, it is quite rewarding, right? So it's very, very hard to do startups in this space.

0:34:15 Uh, I always like to use the phrase it's kind of like playing the game on hard mode, but it's, it's, uh- [laughs] That's true... it's very rewarding, too, so. [laughs] Um- It's so true.

0:34:23 With that said, let's get to the rapid-fire portion of the interview. But again, for everyone listening, zynflow.com is the website. Uh, we'll link to it in the full write-up, as well as, uh, uh, Sree's LinkedIn profile.

0:34:31 Uh, but first question on the docket, I think I, I think I know, might know the answer, but, um, when you... let's fast-forward a year from now, right? So take us into kinda Q1, Q2 of next year.

0:34:39 What are you most excited about over the, the course of those, those 12 months at ZynFlow? I'm excited about FDA approval, commercialization, and having this technology truly seeing the light of day.

0:34:49 That's the dream- Yeah... is, is access for our patients to commercial availability of this, this device. Yeah, that's cool. That's the thing that I'd be most excited about, too, [laughs] if I was- Yeah, yeah...

0:34:59 sitting in your shoes. Um, um, all right. Since, since co-founding, uh, ZynFlow, you know, 10 years ago, what's the, what's the most, uh, surprising or unexpected thing, uh, that you've, that you've learned?

0:35:09 This one's a tough one for me to, to answer. I mean, it's been... there've been tumultuous times, right? We've seen... We've gone through COVID. We shifted to working from home.

0:35:20 Um, all of that has, has really pressure-tested us, right? [laughs] Um, and I think tough fundraising times, right? Mm-hmm. It's just... And we're still, we're still here.

0:35:30 And I think, you know, oftentimes you hear the story of how hard it is, and that... and it's hard to appreciate until you're in it. But then at, at the end of the day, you just take it step by step. Mm-hmm.

0:35:41 And maybe that's the most surprising thing, is just at the end of the day, we're still here.

0:35:44 We're still standing, and I think you have to, you have to approach it with that level of, you know, intensity perhaps- Mm-hmm... [laughs] and, and endurance.

0:35:54 And if you do, and you're surrounded by people who are willing to take that journey with you, then, then you're gonna be there at the end of the day and, and still standing. And- Mm...

0:36:02 so that's what I, I think I'm most proud of, is having endured all that, and, and we're still here. And like I said, I'm most excited about commercialization next year. Yeah.

0:36:10 Cue the music, you know, We're Still Standing. > [laughs] Uh, that's, that's good. Yeah.

0:36:16 But, but, uh, you know, I mean, we're, we're joking around, uh, joking ar- about it, but I, I'm sure, like, there's, there's gonna be startup folks that are listening and thinking, "God, I mean, this, this, this challenge that we're facing is just too much," right?

0:36:27 But just know that, gosh, almost every startup goes through some, you know, a, a myriad of, of, of challenges that almost seem too much, you know? And it's just, it's sort of part, part of the, part of the game, right?

0:36:36 Part of the- One step at a time. Yeah, one step. One step at a time. That's a good, good, uh, good framework. Um, let's pretend we're in, uh, your neck of the woods in Silicon Valley.

0:36:43 You've got a, a room full of med tech entrepreneurs.

0:36:46 What's the one most important lesson that you wanna, or the single most important lesson you wanna leave them with, you know, if they're gonna be best positioned to kinda have some sort of a success with their startup?

0:36:55 You know, one thing I think as founders, right, you, you come up with this concept. Sometimes you're married to that concept. You're just sort of, you're so entrenched in it, you think it's the right thing.

0:37:04 I think one thing that it's, is hard to do is to take critical feedback, right? We're, we're, we have this idea. We, we love it, and we, we treat it like our child sometimes.

0:37:16 And one of the things that we did, I think, really well early on is taking that critical feedback with an open mind. You know, stent-like devices have been used in BPH, and so, so we were pressure-tested on that a lot.

0:37:28 Don't surround yourself with yes-men, right? Mm. Surround yourself with people who are going to challenge you, 'cause at the end of the day, again, 10 years down the road, you will not remain unchallenged. [laughs] Mm.

0:37:38 And so you have to take that with an open mind and make sure you incorporate that into your plans, you know?

0:37:44 And, and maybe at the end of the day they're not correct about that criticism or whatever, but you have to be ready to answer those questions. So take that critical feedback seriously, and with- Yeah...

0:37:53 with an open mind. Good stuff. Yeah. And then the other thing, like, you know, there are setbacks. There will always be, always be setbacks.

0:37:59 There'll, there'll be things that, you know, feel like you took two steps forward and one step back, but that's still progress. Mm. And sometimes we, we learn best from those setbacks, right?

0:38:08 And that's, it's all about the journey at the end of the day. Like, you know, it's always worthwhile to pursue something in life sciences.

0:38:16 It's always worthwhile to do our best to improve healthcare and provide better, better technology to our patients.

0:38:22 And so in our environment, especially in Silicon Valley, at the end of the day, you, you learn from those lessons. And there's not a high chance of success, right? Mm.

0:38:31 It's a low chance of success, but even if you don't get through the pivotal trial, even if you don't get that next round of funding, at the end of the day, you will be a better professional- Mm...

0:38:41 at, uh, you know, at the end of it. And, and it will, it will benefit your career in a really meaningful way. Yep, no doubt. Most, most swings are worth it in this, uh, in this arena, for sure. Yeah. Yeah. Exactly.

0:38:52 All right, last question I've got for you, um, Shriya, is, um, take us back to maybe before the BioDesign, maybe a little bit earlier in your, in your, in your career. Call it, you know, mid to late 20s.

0:39:01 Um, is there anything, uh, you know, you'd whisper in the, the ear, the ears of, of the younger version of yourself? You know, one thing I like to say is, um, and it sounds a little hither tither, I suppose- Mm-hmm...

0:39:11 but it's, uh, the journey is the destination. Mm. In other words, your path to wherever you get to is, is almost more important than where you land, and I think we all have a tendency to sort of take that for granted.

0:39:24 We're so, like, okay, maybe we're focused on the exit, right? Especially as entrepreneurs, and it's like, it's been, it's been, it's been a decade, [laughs] as you talked about.

0:39:33 [laughs] And so, and there have been people around me that have really, you know, that ha- that have made this such a pivotal part of my career.

0:39:40 We all have a tendency, I think, to take that journey, to take the people around us perhaps for granted- Right...

0:39:45 as we're staring at the, at the finish line, but those are the people that you're toasting with, you know, with the small wins along the road.

0:39:52 These are your ride or die people, and so understand, appreciate those relationships. Don't take them for granted. They're vital to your, to your success in so many ways.

0:40:01 That's a really g- good way to, good way to wrap it up. Yeah. And t- and take more pictures along the journey, right? Uh- [laughs] Yeah.

0:40:06 [laughs] Those are always, [laughs] always fun to look, look back on, and I don't think we ever- I-... do enough of, like, documenting that, you know, along the way. That's a good point.

0:40:14 So I have, I have, uh, one of our, uh, advisors told me to take a photo of our, of our first lab. Yeah. Um, and he's like, "This'll go, this'll go in the record books."

0:40:22 And I'm like, "Oh, whatever," and I took it anyway, but you know, I'm secure. Yeah. [laughs] I know, I know.

0:40:27 There, there's times when I, I, I, I look back and think, "Oh, I wish I had a picture of, uh, of, of that," right, as a, as a memory. But, uh, this has been fun.

0:40:33 Um, I really appreciate you, you know, taking time of, uh, I, I, I'm gonna assume a very busy schedule to, to do the interview and, you know, to, to help coach up and offer up some, some words of wisdom, right, to other, other med tech folks that are, that are listening to this.

0:40:44 And again, for everyone, uh, everyone that's, uh, that's got this far, zynflow.com is the website, just as it sounds, zynflow.com. We'll link to it in the full writeup on MedSider.

0:40:53 If you're new to MedSider, all of these podcast interviews, um, are accompanied by a longer form article that kind of summarizes a lot of the key experiences and, and lessons learned that are shared throughout the course of this discussion.

0:41:02 So thank, definitely encourage everyone to, to head there. But, um, Shriya, again, I'll have you hold on the line, but thanks again for, for doing this. Uh- Yeah. Thanks so much, Scott...

0:41:09 I'm, I'm glad we were able to finally make it work. Yeah. This was fun. Thanks for inviting me. I appreciate it. All right. And for everyone listening, thanks for your attention as always.

0:41:16 Until the next episode of MedSider Goes Live, everyone take care. [outro music] Hey, it's Scott again. One quick thing before you go.

0:41:22 You see, I love bringing you insightful conversations with the best founders and CEOs of medical device and health technology startups, but here's the thing.

0:41:28 I'd be super grateful if you could help me reach even more ambitious doers who share our passion.

0:41:32 So if you found value in this podcast, if you found yourself nodding your head while listening, or if you simply enjoy what we're doing with MedSider, please take a moment to leave us a review. It's super easy.

0:41:41 Just open your Apple Podcasts app or the podcasts app of your choice, search for our show, and scroll down to the ratings and review section.

0:41:47 Leave your honest thoughts and hit that five-star rating if you think we're worthy.

0:41:50 Your feedback is incredibly important, and it's the best way to ensure we keep bringing you awesome discussions with leading founders and CEOs. So take a moment to be a good friend and leave that review today.

0:41:59 As always, thanks for being a part of our journey and for helping MedSider continue to grow and evolve. Your support is greatly appreciated. All right, enough talk about reviews.

0:42:06 Stay tuned for another informative episode coming at you soon. [outro music]